Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil P Robertson

Showing results (111-120 of 129) with videos related to

Pageof 13
Sort By:
Neurology|June 15, 2023
Global Barriers to the Diagnosis of Multiple Sclerosis: Data From the Multiple Sclerosis International Federation Atlas of MS, Third EditionAndrew J Solomon, Ruth Ann Marrie, Shanthi Viswanathan, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 6, 2020
Detecting and predicting neutralization of alemtuzumab responses in MSGauri Saxena, James M Moore, Meleri Jones, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 16, 2026
Genetic subtypes associated with multiple sclerosis severity and response to treatmentKarim L Kreft, Nienke J Mekkes, Emeka Uzochukwu, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 14, 2011
The motor phenotype of Parkinson's disease in relation to age at onsetMirdhu M Wickremaratchi, M Duleeka W Knipe, B S Dwarakanath Sastry, et al.
Journal of Neuroinflammation|November 23, 2020
CCN3 is dynamically regulated by treatment and disease state in multiple sclerosisMichelle Naughton, Jill Moffat, George Eleftheriadis, et al.
Therapeutic Advances in Neurological Disorders|May 25, 2026
Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countriesCarmen de Keijzer, Jian-Yu E, Qian Yang, et al.
Scientific Reports|October 18, 2016
Targeted suppression of autoreactive CD8<sup>+</sup> T-cell activation using blocking anti-CD8 antibodiesMathew Clement, James A Pearson, Stephanie Gras, et al.
Multiple Sclerosis and Related Disorders|June 14, 2022
Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosisEmma C Tallantyre, Martin J Scurr, Nicola Vickaryous, et al.
JAMA Network Open|January 10, 2022
Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United KingdomChanjira Satukijchai, Romina Mariano, Silvia Messina, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 11, 2023
Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccinationSafiya A Zaloum, Callum H Wood, Pooja Tank, et al.
Pageof 13

Showing results (111-120 of 129) with videos related to

Sort By:
Pageof 13
Neurology|June 15, 2023
Global Barriers to the Diagnosis of Multiple Sclerosis: Data From the Multiple Sclerosis International Federation Atlas of MS, Third EditionAndrew J Solomon, Ruth Ann Marrie, Shanthi Viswanathan, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|June 6, 2020
Detecting and predicting neutralization of alemtuzumab responses in MSGauri Saxena, James M Moore, Meleri Jones, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 16, 2026
Genetic subtypes associated with multiple sclerosis severity and response to treatmentKarim L Kreft, Nienke J Mekkes, Emeka Uzochukwu, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|January 14, 2011
The motor phenotype of Parkinson's disease in relation to age at onsetMirdhu M Wickremaratchi, M Duleeka W Knipe, B S Dwarakanath Sastry, et al.
Journal of Neuroinflammation|November 23, 2020
CCN3 is dynamically regulated by treatment and disease state in multiple sclerosisMichelle Naughton, Jill Moffat, George Eleftheriadis, et al.
Therapeutic Advances in Neurological Disorders|May 25, 2026
Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countriesCarmen de Keijzer, Jian-Yu E, Qian Yang, et al.
Scientific Reports|October 18, 2016
Targeted suppression of autoreactive CD8<sup>+</sup> T-cell activation using blocking anti-CD8 antibodiesMathew Clement, James A Pearson, Stephanie Gras, et al.
Multiple Sclerosis and Related Disorders|June 14, 2022
Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosisEmma C Tallantyre, Martin J Scurr, Nicola Vickaryous, et al.
JAMA Network Open|January 10, 2022
Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease in the United KingdomChanjira Satukijchai, Romina Mariano, Silvia Messina, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 11, 2023
Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccinationSafiya A Zaloum, Callum H Wood, Pooja Tank, et al.
Pageof 13